CervoMed reports Q3 2025 grant revenue of $0.3 million

Reuters

Nov 10

<a href="https://laohu8.com/S/CRVO">CervoMed</a> reports Q3 2025 grant revenue of $0.3 million

CervoMed Inc. reported a cash position of $27.3 million as of September 30, 2025, down from $38.9 million at December 31, 2024. The company stated that its current cash, cash equivalents, and marketable securities are expected to fund operations into the third quarter of 2026. Grant revenue for the third quarter of 2025 was $0.3 million, compared to $1.9 million in the same period of 2024, reflecting the completion of the initial and extension phases of the RewinD-LB trial. During the quarter, CervoMed announced new Phase 2b RewinD-LB trial data and the appointment of Matthew Winton as Chief Commercial and Business Officer, as well as David Quigley to the Board of Directors. Initial biomarker data from a Phase 2a trial in frontotemporal dementia and topline results from a Phase 2a trial in stroke recovery are expected in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2582587373"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582587373\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582587373?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 20:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582587373","market":"fut","top_or_hot":-1,"title":"CervoMed reports Q3 2025 grant revenue of $0.3 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CRVO\">CervoMed</a> reports Q3 2025 grant revenue of $0.3 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CervoMed Inc. reported a cash position of $27.3 million as of September 30, 2025, down from $38.9 million at December 31, 2024. The company stated that its current cash, cash equivalents, and marketable securities are expected to fund operations into the third quarter of 2026. Grant revenue for the third quarter of 2025 was $0.3 million, compared to $1.9 million in the same period of 2024, reflecting the completion of the initial and extension phases of the RewinD-LB trial. During the quarter, CervoMed announced new Phase 2b RewinD-LB trial data and the appointment of Matthew Winton as Chief Commercial and Business Officer, as well as David Quigley to the Board of Directors. Initial biomarker data from a Phase 2a trial in frontotemporal dementia and topline results from a Phase 2a trial in stroke recovery are expected in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CervoMed reports Q3 2025 grant revenue of $0.3 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCervoMed reports Q3 2025 grant revenue of $0.3 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-10 20:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CRVO\">CervoMed</a> reports Q3 2025 grant revenue of $0.3 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CervoMed Inc. reported a cash position of $27.3 million as of September 30, 2025, down from $38.9 million at December 31, 2024. The company stated that its current cash, cash equivalents, and marketable securities are expected to fund operations into the third quarter of 2026. Grant revenue for the third quarter of 2025 was $0.3 million, compared to $1.9 million in the same period of 2024, reflecting the completion of the initial and extension phases of the RewinD-LB trial. During the quarter, CervoMed announced new Phase 2b RewinD-LB trial data and the appointment of Matthew Winton as Chief Commercial and Business Officer, as well as David Quigley to the Board of Directors. Initial biomarker data from a Phase 2a trial in frontotemporal dementia and topline results from a Phase 2a trial in stroke recovery are expected in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL8bHgRq:1","article_id":"2582587373","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582587373","pubTimestamp":1762776360,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CervoMed Inc. reported a cash position of $27.3 million as of September 30, 2025, down from $38.9 million at December 31, 2024. The company stated that its current cash, cash equivalents, and marketable securities are expected to fund operations into the third quarter of 2026. Grant revenue for the third quarter of 2025 was $0.3 million, compared to $1.9 million in the same period of 2024, reflecting the completion of the initial and extension phases of the RewinD-LB trial. During the quarter, CervoMed announced new Phase 2b RewinD-LB trial data and the appointment of Matthew Winton as Chief Commercial and Business Officer, as well as David Quigley to the Board of Directors. Initial biomarker data from a Phase 2a trial in frontotemporal dementia and topline results from a Phase 2a trial in stroke recovery are expected in 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CRVO":"CervoMed"},"translate_title":"CervoMed报告2025年第三季度赠款收入为30万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRVO":0.9},"content_text":"CervoMed reports Q3 2025 grant revenue of $0.3 million\n    \n\n        CervoMed Inc. reported a cash position of $27.3 million as of September 30, 2025, down from $38.9 million at December 31, 2024. The company stated that its current cash, cash equivalents, and marketable securities are expected to fund operations into the third quarter of 2026. Grant revenue for the third quarter of 2025 was $0.3 million, compared to $1.9 million in the same period of 2024, reflecting the completion of the initial and extension phases of the RewinD-LB trial. During the quarter, CervoMed announced new Phase 2b RewinD-LB trial data and the appointment of Matthew Winton as Chief Commercial and Business Officer, as well as David Quigley to the Board of Directors. Initial biomarker data from a Phase 2a trial in frontotemporal dementia and topline results from a Phase 2a trial in stroke recovery are expected in 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}